Jefferies Financial Group Inc. Buys Shares of 2,199,652 Urogen Pharma $URGN

Jefferies Financial Group Inc. acquired a new stake in Urogen Pharma (NASDAQ:URGN) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 2,199,652 shares of the company’s stock, valued at approximately $80,947,000. Urogen Pharma comprises approximately 0.5% of Jefferies Financial Group Inc.’s investment portfolio, making the stock its 19th largest holding.

A number of other institutional investors have also made changes to their positions in the business. Paradigm Biocapital Advisors LP bought a new stake in Urogen Pharma during the 3rd quarter worth about $84,111,000. BlackRock Inc. acquired a new stake in shares of Urogen Pharma in the second quarter valued at about $117,814,000. Soleus Capital Management L.P. bought a new stake in shares of Urogen Pharma during the 2nd quarter worth approximately $29,934,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Urogen Pharma in the fourth quarter valued at $26,350,000. Finally, MPM Bioimpact LLC grew its holdings in Urogen Pharma by 597.3% during the fourth quarter. MPM Bioimpact LLC now owns 941,378 shares of the company’s stock worth $22,047,000 after purchasing an additional 806,378 shares during the period. Institutional investors own 91.29% of the company’s stock.

Urogen Pharma Price Performance

Shares of NASDAQ:URGN opened at $45.50 on Friday. The company’s fifty day moving average price is $41.61 and its 200-day moving average price is $29.85. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of -22.98 and a beta of 1.57. Urogen Pharma has a one year low of $15.86 and a one year high of $50.81.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $72.46 million for the quarter, compared to the consensus estimate of $63.55 million. As a group, equities research analysts expect that Urogen Pharma will post -0.2 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on URGN. TD Cowen upped their price target on shares of Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. LADENBURG THALM/SH SH began coverage on Urogen Pharma in a research note on Monday, May 11th. They issued a “buy” rating and a $43.00 target price on the stock. Oppenheimer lifted their price objective on shares of Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. Guggenheim increased their price target on Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, UBS Group reissued a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $50.38.

Insiders Place Their Bets

In related news, insider Mark Schoenberg sold 60,677 shares of the company’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $47.05, for a total transaction of $2,854,852.85. Following the completion of the sale, the insider directly owned 59,086 shares in the company, valued at $2,779,996.30. This represents a 50.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders sold a total of 85,899 shares of company stock valued at $3,747,513 in the last ninety days. Insiders own 4.80% of the company’s stock.

Urogen Pharma Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.